Cantor Fitzgerald: 'We now expect apitegromab to have near complete market share'
Tweet Send to a Friend
Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating and {REMOVEPT} price target on Scholar Rock (NASDAQ: SRRK).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


